Shandong Jincheng Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Jincheng Pharmaceutical", stock code: 300233) was founded in 2004, a national high-tech enterprise and a listed enterprise on the Growth Enterprise Market. At present, the company owns Beijing jincheng jincheng strategy pharmaceutical technology co., LTD., Beijing thayer Jin Chengsu wisdom pharmaceutical co., LTD., Shanghai pharmaceutical co., LTD., guangdong Jin Chengjin pharmaceutical co., LTD., shandong jincheng pharmaceutical chemical co., LTD., shandong jincheng biological pharmaceutical co., LTD., Italy haibao shows 23 JiaCan holdings co., LTD., etc. Through the two-wheeled development model of "industry + capital", the company has built and formed a pharmaceutical and health pharmaceutical industrial chain with unique Jincheng characteristics. Its business scope covers biopharmaceutical, cephalosporin pharmaceutical intermediates, characteristic APIs, terminal preparations, health care products, new materials, emerging high-end medical devices and other industrial fields. And has formed an annual operating income of 3 billion yuan, the total assets of nearly 5 billion industry scale.

Company is three or four generation cephalosporin intermediates, API, biological pharmacy, terminal, and children's products for the main business of scientific research, production enterprises, including cephalosporins pharmaceutical intermediates product sales, sales income is the industry leader for many years, is an important biological pharmaceutical production base and domestic well-known medical health industry group. The main products include nearly 100 kinds of glutathione (anthocyanin), nifuratel capsule (Lanyi), bisoprolol fumarate capsule (Loya), compound xylostellum aluminum-magnesium tablet (Drefu), cefazolin sodium (Ansfancef), AE- active ester, furan ammonium salt and so on.